Treatment with a single dose of the anti-ANGPTL3/8-specific monoclonal antibody LY3475766 resulted in robust, dose-dependent increases (almost ninefold) in circulating ANGPTL3/8 levels in participants with mixed hyperlipidemia. Here, ANGPTL3 is linked to Combined hyperlipidemia.